Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Phase 3CompletedDevelopment Stage
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Jan 1, 2014 → May 1, 2017
About Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) is a phase 3 stage product being developed by ImmunityBio for Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02049905. Target conditions include Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02049905 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma